MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2026-27)
- Udyam number
- UDYAM-MH-19-0021173
Market Cap
₹30.18 Cr
CBPL · BSE
Share Price
₹39.00
-2.50% today
Revenue
₹116 Cr
FY 2025-26 · +30.9% YoY
EBITDA
₹3.86 Cr
Margin 3.3%
Net Profit
₹3.05 Cr
FY 2025-26 · +335.7% YoY
P/E (TTM)
9.9x
P/B 0.9x
ROE
9.7%
ROCE 12.2%
Debt / Equity
0.59
Interest cover 72.5x
About Chandra Bhagat Pharma Limited
Data last updated:
Chandra Bhagat Pharma Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 10 March 2003 and has been in existence for over 23 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24230MH2003PLC139534. Its GSTIN is 27AACCC1056D1Z6 (Maharashtra). The company holds 3 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 542934.
The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹7.55 Cr. It was formerly known as Chandra Bhagat Pharma Private Limited. It is led by directors including Hemant Chandravadan Bhagat (Managing Director) and Pranav Hemant Bhagat (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 323 – F Bhagat Bhuvan Dr.Ambedkar Road Matunga (East), Mumbai, Maharashtra, India – 400019.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹116.27 Cr, a growth of 30.9% compared to the previous year. For the same year it recorded a net profit of ₹3.05 Cr (net margin 2.6%) and EBITDA of ₹3.86 Cr (EBITDA margin 3.3%). The net worth stands at ₹33.13 Cr (up 10.5% YoY). Total assets are valued at ₹49.66 Cr (down 2.4% YoY).
The company has about 31 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Chandra Bhagat Pharma. As per MCA filings, the company has open charges of ₹47.5 Cr and satisfied charges of ₹41.15 Cr on record. Court records list 31 cases involving the company, including 5 filed by the company and 26 filed against it; 7 cases are pending. The company has 63 deals on record (62 market trades, 1 ipo); the latest was in June 2026. Its 8 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Chiron Behring Vaccines Private Limited with revenue of ₹94.53 Cr.
Chandra Bhagat Pharma Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-19-0021173). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website cbcpharma.com.
Company details
CIN L24230MH2003PLC139534
Registration Number 139534
Incorporation Date 10 March 2003
ROC Mumbai
Listing Status Listed - Listed on BSE (542934)
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-MH-19-0021173
CIN history
Chandra Bhagat Pharma has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24230MH2003PLC139534, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230MH2003PLC139534 | Current |
| U24230MH2003PTC139534 | Previous |
| U24230MH2003PLC139534 | Previous |
Key People
Hemant Chandravadan Bhagat Managing Director Pranav Hemant Bhagat Whole-Time Director Ravindra Gajanan Awati Director Recognitions & Rankings of Chandra Bhagat Pharma
Contact details
Chandra Bhagat Pharma Limited's registered office is in Mumbai, Maharashtra. Its website is cbcpharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address323 – F Bhagat Bhuvan Dr.Ambedkar Road Matunga (East), Mumbai, Maharashtra, India – 400019
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Chandra Bhagat Pharma Limited, buy the company report.
Comprehensive company report
Chandra Bhagat Pharma Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Chandra Bhagat Pharma operates one associated brand: Chandra Bhagat Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Importer, exporter, and marketer of pharmaceutical products | cbcpharma.com |
Business activity
The main business activity of Chandra Bhagat Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Chandra Bhagat Pharma Limited, buy the company report.
Financials of Chandra Bhagat Pharma Limited
FY 2025-26 filings availableChandra Bhagat Pharma Limited reported revenue of ₹116.27 Cr (up 30.9% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue
₹116 Cr
+30.9% YoY
EBITDA
₹3.86 Cr
+512.7% YoY
Profit After Tax
₹3.05 Cr
+335.7% YoY
Net Worth
₹33.13 Cr
+10.5% YoY
Total Assets
₹49.66 Cr
-2.4% YoY
Total Debt
₹16.51 Cr
-20.9% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 116 | 88.81 | 221 | 120 | 94.08 | 70.70 | 93.98 |
| Revenue growth | +30.9% | -59.9% | +85.0% | +27.2% | +33.1% | -24.8% | - |
| EBITDA | 3.86 | 0.63 | (7.05) | 3.33 | 2.83 | 3.68 | 3.12 |
| EBITDA margin | +3.3% | +0.7% | -3.2% | +2.8% | +3.0% | +5.2% | +3.3% |
| Profit before tax | 4.11 | 1.16 | 2.25 | 1.15 | 1.09 | 0.28 | 0.42 |
| Net profit | 3.05 | 0.70 | 1.51 | 0.90 | 0.79 | 0.19 | 0.31 |
| Net profit margin | +2.6% | +0.8% | +0.7% | +0.8% | +0.8% | +0.3% | +0.3% |
| EPS (₹) | 4.04 | 1.14 | 2.03 | 1.20 | 1.06 | 0.25 | 0.42 |
| Balance sheet | |||||||
| Total assets | 49.66 | 50.86 | 45.76 | 48.64 | 50.10 | 56.52 | 59.71 |
| Net worth | 33.13 | 29.97 | 29.01 | 27.48 | 26.68 | 25.88 | 25.69 |
| Total debt | 16.51 | 20.86 | 16.43 | 18.94 | 21.11 | 27.07 | 29.93 |
| Cash & bank | 3.11 | 0.67 | 4.96 | 6.44 | 5.68 | 2.82 | 0.05 |
| Net working capital | 41.46 | 43.85 | 41.75 | 46.06 | 48.14 | 54.76 | 57.08 |
| Cash flow | |||||||
| Cash from operations | 9.24 | (5.71) | 6.18 | 5.26 | 12.40 | 8.33 | (7.41) |
| Cash from investing | (0.43) | (0.78) | (1.85) | (0.06) | 0.09 | 0.12 | 0.05 |
| Cash from financing | (6.36) | 2.19 | (5.80) | (4.45) | (9.62) | (6.42) | 6.94 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 24 Oct 2026
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 116 | 88.81 | 221 | 120 | 94.08 | 70.70 | 93.98 |
| Revenue growth | +30.9% | -59.9% | +85.0% | +27.2% | +33.1% | -24.8% | - |
| Other income | 3.35 | 3.43 | 11.33 | 0.29 | 1.62 | 0.48 | 0.44 |
| Total expenses | 112 | 88.18 | 228 | 116 | 91.25 | 67.02 | 90.86 |
| Employee cost | 2.53 | 2.03 | 2.18 | 1.32 | 1.52 | 1.85 | 2.25 |
| EBITDA | 3.86 | 0.63 | (7.05) | 3.33 | 2.83 | 3.68 | 3.12 |
| EBITDA margin | +3.3% | +0.7% | -3.2% | +2.8% | +3.0% | +5.2% | +3.3% |
| Depreciation | 1.10 | 0.95 | 0.64 | 0.27 | 0.12 | 0.12 | 0.03 |
| Interest | 2.00 | 1.95 | 1.39 | 2.20 | 3.24 | 3.76 | 3.11 |
| Profit before tax | 4.11 | 1.16 | 2.25 | 1.15 | 1.09 | 0.28 | 0.42 |
| Tax | 1.06 | 0.31 | 0.74 | 0.25 | 0.30 | 0.09 | 0.11 |
| Net profit | 3.05 | 0.70 | 1.51 | 0.90 | 0.79 | 0.19 | 0.31 |
| Net profit margin | +2.6% | +0.8% | +0.7% | +0.8% | +0.8% | +0.3% | +0.3% |
| EPS (₹) | 4.04 | 1.14 | 2.03 | 1.20 | 1.06 | 0.25 | 0.42 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 7.55 | 7.55 | 7.55 | 7.55 | 7.55 | 7.55 | 7.55 |
| Reserves & surplus | 25.58 | 22.42 | 21.46 | 19.93 | 19.13 | 18.33 | 18.14 |
| Shareholders' funds (net worth) | 33.13 | 29.97 | 29.01 | 27.48 | 26.68 | 25.88 | 25.69 |
| Secured loans | 14.64 | 19.09 | 14.64 | 14.37 | 16.12 | 18.82 | 17.66 |
| Unsecured loans | 1.87 | 1.77 | 1.79 | 4.57 | 4.99 | 8.25 | 12.27 |
| Total debt | 16.51 | 20.86 | 16.43 | 18.94 | 21.11 | 27.07 | 29.93 |
| Total liabilities | 49.66 | 50.86 | 45.76 | 48.64 | 50.10 | 56.52 | 59.71 |
| Assets | |||||||
| Gross block | 5.17 | 4.25 | 3.78 | 1.50 | 1.13 | 1.26 | 1.24 |
| Net block | 2.62 | 2.62 | 2.53 | 0.73 | 0.47 | 0.42 | 0.43 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.67 | 0.14 | 0.13 | 0.11 | 0.22 | 0.00 | 0.75 |
| Inventories | 4.67 | 0.69 | 8.68 | 29.08 | 34.16 | 35.14 | 43.90 |
| Sundry debtors | 54.62 | 35.95 | 39.45 | 8.19 | 15.00 | 15.42 | 14.03 |
| Cash & bank balances | 3.11 | 0.67 | 4.96 | 6.44 | 5.68 | 2.82 | 0.05 |
| Loans & advances | 23.60 | 57.21 | 44.70 | 14.28 | 15.66 | 16.63 | 14.14 |
| Total current assets | 86.00 | 94.52 | 97.79 | 57.99 | 70.50 | 70.01 | 72.12 |
| Total current liabilities | 44.54 | 50.67 | 56.04 | 11.93 | 22.36 | 15.25 | 15.04 |
| Net working capital | 41.46 | 43.85 | 41.75 | 46.06 | 48.14 | 54.76 | 57.08 |
| Total assets | 49.66 | 50.86 | 45.76 | 48.64 | 50.10 | 56.52 | 59.71 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.67 | 4.96 | 6.44 | 5.68 | 2.82 | 0.80 | 0.48 |
| Net cash from operating activities | 9.24 | (5.71) | 6.18 | 5.26 | 12.40 | 8.33 | (7.41) |
| Net cash from investing activities | (0.43) | (0.78) | (1.85) | (0.06) | 0.09 | 0.12 | 0.05 |
| Net cash from financing activities | (6.36) | 2.19 | (5.80) | (4.45) | (9.62) | (6.42) | 6.94 |
| Net change in cash | 2.45 | (4.30) | (1.48) | 0.76 | 2.86 | 2.02 | (0.43) |
| Closing cash | 3.11 | 0.67 | 4.96 | 6.44 | 5.68 | 2.82 | 0.05 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +30.9% | -59.9% | +85.0% | +27.2% | +33.1% | -24.8% | - |
| EBITDA growth | +512.7% | +108.9% | -311.7% | +17.7% | -23.1% | +18.0% | - |
| PBT growth | +254.3% | -48.4% | +95.7% | +5.5% | +289.3% | -33.3% | -53.3% |
| Net income growth | +335.7% | -53.6% | +67.8% | +13.9% | +315.8% | -38.7% | - |
| Revenue CAGR (3Y) | -1.0% | -1.9% | +46.3% | +8.4% | -4.0% | -10.0% | +1.5% |
| EBITDA CAGR (3Y) | +5.1% | -39.4% | - | +2.2% | -15.0% | -7.1% | -10.6% |
| Profitability & leverage | |||||||
| Net income margin | +2.6% | +1.0% | +0.7% | +0.8% | +0.8% | +0.3% | +0.3% |
| Return on capital employed | +12.2% | +6.0% | +7.7% | +6.8% | +8.1% | +7.0% | +6.4% |
| Return on net worth | +9.7% | +2.4% | +5.4% | +3.4% | +3.0% | +0.7% | +1.5% |
| Debt / equity | 0.59 | 0.63 | 0.63 | 0.74 | 0.92 | 1.11 | 1.52 |
| Long-term debt / equity | 0.08 | 0.06 | 0.09 | 0.17 | 0.28 | 0.39 | 0.56 |
| Interest cover | 72.46 | -609.38 | -18.08 | 71.90 | 119.56 | 105.62 | 100.65 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 24.69 | 22.12 | 83.85 | 91.00 | 78.73 | 56.56 | 75.79 |
| Inventory turnover | 43.38 | 18.96 | 11.73 | 3.78 | 2.72 | 1.79 | 2.14 |
| Debtors turnover | 2.57 | 2.36 | 9.29 | 10.32 | 6.19 | 4.80 | 4.66 |
| EPS (₹) | 4.04 | 1.14 | 2.03 | 1.20 | 1.06 | 0.25 | 0.42 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 43.90 | 39.72 | 38.45 | 36.42 | 35.35 | 34.30 | 34.05 |
To see the full year-wise statements and ratios of Chandra Bhagat Pharma Limited, buy the company report.
Board of directors of Chandra Bhagat Pharma Limited
Chandra Bhagat Pharma has 5 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ravindra Gajanan Awati Also directs: Jagatik Marathi Chamber of Commerce and Industries | Director | 31 Aug 2019 | 7 Years 1 Months | Current |
| Abha Praveen Doshi | Director | 15 Jul 2019 | 7 Years 3 Months | Current |
| Hemant Chandravadan Bhagat | Managing Director | 10 Mar 2003 | 23 Years 7 Months | Current |
| Pranav Hemant Bhagat Also directs: Indo-Persian Gulf Chamber of Commerce | Whole-Time Director | 17 May 2004 | 22 Years 5 Months | Current |
| Prachi Pranav Bhagat Also directs: Indo-Persian Gulf Chamber of Commerce | Director | 25 Sep 2018 | 8 Years 1 Months | Current |
Peer comparison
Chandra Bhagat Pharma Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Chandra Bhagat Pharma Limitedthis company | ₹116.27 Cr (FY 2026) | ₹3.05 Cr | 2.6% | 30.9% | 31 | Mumbai, Maharashtra, India |
| Chiron Behring Vaccines Private Limited | ₹94.53 Cr (FY 2025) | 30.0% | Bhor, Maharashtra, India | |||
| Cosmas Research Lab Limited | ₹93.42 Cr (FY 2025) | 60.0% | Ludhiana, Punjab, India | |||
| Centurion Healthcare Private Limited | ₹92.65 Cr (FY 2024) | 21.0% | Vadodara, Gujarat, India | |||
| Lovincare Cosmetics Private Limited | ₹92.22 Cr (FY 2025) | 22.0% | Himachal Pradesh, India | |||
| Twentyfirst Century Pharmaceuticals Private Limited | ₹91.89 Cr (FY 2022) | 32.0% | Chennai, Tamil Nadu, India | |||
| Lifecare Neuro Products Limited | ₹91.88 Cr (FY 2024) | 14.0% | Nalagarh, Himachal Pradesh, India | |||
| Sydler Remedies Private Limited | ₹91.31 Cr (FY 2025) | -30.0% | Aurangabad, Maharashtra, India | |||
| S. A. Pharmachem Private Limited | ₹91.25 Cr (FY 2025) | -54.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Chandra Bhagat Pharma Limited, buy the company report.
Auditor
Chandra Bhagat Pharma Limited is audited by A Y & COMPANY for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| A Y & COMPANY | FY 2023 | 020829C |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 73.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 27.00%.
Sep 2026
QUARTER
73.00% Promoters
27.00% Retail & Others
Promoter holding - history
Now 73.00% · Sep 2026High 73.00% · Sep 2026Low 71.20% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 73.00% | 72.20% | 71.20% | 71.20% |
| Public | 27.00% | 27.80% | 28.80% | 28.80% |
Charges & borrowings
Open charges
₹47.5 Cr
Satisfied charges
₹41.15 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 29 Jul 2026 | 101357317 | Axis Bank Limited | ₹1.62 Cr | Open | |
| 13 Jul 2026 | 101338774 | Axis Bank Limited | ₹23.06 Cr | Open | |
| 16 Jan 2025 | 101049748 | Canara Bank | ₹30 Lakh | Open | |
| 28 Oct 2020 | 100396299 | Axis Bank Limited | ₹3.25 Cr | Open | |
| 23 Feb 2018 | 100162599 | Axis Bank Limited | ₹19.27 Cr | Open |
To see the full charge records of Chandra Bhagat Pharma Limited, buy the company report.
Total charge records: 13 View all charges
Deals & funding
Chandra Bhagat Pharma Limited has 63 deals on record (62 market trades, 1 ipo); the latest was in June 2026.
Total deals
63
Market trades
62
IPO
1
Deals on record (5 of 63)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jun 2026 | Market trade | ₹21.6 Lakh | Seller: Team Anamika Algo Limited |
| May 2026 | Market trade | ₹24.7 Lakh | Buyer: Bengal Tiger Capital Advisors LLP Seller: Team Anamika Algo Limited |
| Nov 2024 | Market trade | ₹44.1 Lakh | Buyer: an individual Seller: Piyush Securities Pvt Ltd |
| Nov 2024 | Market trade | ₹40.9 Lakh | Buyer: Piyush Securities Pvt Ltd Seller: Kapil Agarwal Huf . |
| Nov 2024 | Market trade | ₹71.4 Lakh | Buyer: Sunflower Broking Private Limited Seller: Alacrity Securities Limited , Sunflower Broking Private Limited |
To see the full deal history of Chandra Bhagat Pharma Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Chandra Bhagat Pharma Limited has 31 court cases on record: 5 filed by Chandra Bhagat Pharma, 26 filed against it. 7 cases are pending and 24 are disposed.
Total cases
31
Filed by the company
5
Filed against the company
26
Pending
7
Disposed
24
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 25 | 23 | 4 |
| High courts | 5 | 2 | 3 |
| NCLT | 1 | 1 | 0 |
Cases on record (5 of 31)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Rajasthan | Court case (CFA) | Filed by the company against Rajasthan Medical Services Corporation Limited and 1 other | Pending |
| High Court of Rajasthan | Court case (CSTAY) | Filed by the company against Rajasthan Medical Services Corporation Limited | Pending |
| High Court | Writ petition | Filed against the company by Bharat Serums and Vaccines Limited Tarun Kumar Mishra and 1 other | Pending |
| High Court of Rajasthan | Court case (CMCC) | Filed by the company against Rajasthan Medical Services Corporation Limited | Disposed |
| District court, Mumbai City Civil Court, Maharashtra | Commercial matter | Filed against the company by Gufic Biosciences Limited Through Ami Shah | Disposed |
To see the full case history of Chandra Bhagat Pharma Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Chandra Bhagat Pharma Limited was last rated by Care on 25 Jan 2022.
| Rating agency | Rated on | Rating |
|---|---|---|
| Care | 25 Jan 2022 |
To see the full credit ratings and regulatory alerts of Chandra Bhagat Pharma Limited, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Chandra Bhagat Pharma Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Chandra Bhagat Pharma Limited has a workforce of 31 employees on its EPFO records as of Apr 02, 2024, across 1 active EPFO establishment.
Employee count
31
Active EPFO establishments
1
Employee growth
24%
GST
Chandra Bhagat Pharma has 3 GST registrations: 1 active and 2 cancelled or inactive.
Total GSTINs
3
Active
1
Cancelled / inactive
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AACCC1056D1Z6 | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Chandra Bhagat Pharma Limited, buy the company report.
Recent activity
Chandra Bhagat Pharma Limited has 9 board changes on record since 2003: 7 appointments and 2 cessations. The latest: Ravindra Gajanan Awati was appointed as Director on 31 Aug 2019.
Charges
A charge with Axis Bank Limited of Rs. 23.06 Cr registered on 13 Jul 2026 with Charge ID 101338774 was modified on 24 Sep 2026.
Charges
A charge with Axis Bank Limited amounted to Rs. 1.62 Cr with Charge ID 101357317 was registered on 29 Jul 2026.
Charges
A charge with Axis Bank Limited amounted to Rs. 23.06 Cr with Charge ID 101338774 was registered on 13 Jul 2026.
Filing
Chandra Bhagat Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
AGM
Chandra Bhagat Pharma Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Charges
A charge with Canara Bank amounted to Rs. 0.30 Cr with Charge ID 101049748 was registered on 16 Jan 2025.
Charges
A charge registered on 11 Sep 2017 via Charge ID 100130761 with Others was fully satisfied on 11 Nov 2024.
Charges
A charge with Axis Bank Limited of Rs. 19.27 Cr registered on 23 Feb 2018 with Charge ID 100162599 was modified on 28 Jun 2024.
Charges
A charge with Axis Bank Limited of Rs. 3.25 Cr registered on 28 Oct 2020 with Charge ID 100396299 was modified on 06 Feb 2021.
Charges
A charge with Axis Bank Limited amounted to Rs. 3.25 Cr with Charge ID 100396299 was registered on 28 Oct 2020.
Appointed
Ravindra Gajanan Awati was appointed as Director.
Appointed
Abha Praveen Doshi was appointed as Director.
27 earlier events are in the company report.
Frequently asked questions
Chandra Bhagat Pharma is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 10 March 2003 (23+ years old) and is registered under CIN L24230MH2003PLC139534. Listed on BSE: 542934.
Chandra Bhagat Pharma reported revenue of ₹116.27 Cr for FY 2025-26 (up 30.9% YoY) based on standalone financials.
Chandra Bhagat Pharma has 5 current directors:
- Hemant Chandravadan Bhagat - Managing Director
- Pranav Hemant Bhagat - Whole-Time Director
- Ravindra Gajanan Awati - Director
- Abha Praveen Doshi - Director
- Prachi Pranav Bhagat - Director
The latest financial statements of Chandra Bhagat Pharma on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Chandra Bhagat Pharma is 27AACCC1056D1Z6, registered in Maharashtra. The company has 3 GST registrations in all, of which 1 is active and 2 are cancelled or inactive.
The CIN (Corporate Identification Number) of Chandra Bhagat Pharma is L24230MH2003PLC139534. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Chandra Bhagat Pharma is a listed company as per MCA records. Its shares are listed on BSE (code: 542934).
Chandra Bhagat Pharma has 31 court cases on record: 5 filed by the company and 26 filed against it. 7 are pending. Most are in the district courts.
Chandra Bhagat Pharma was incorporated on 10 March 2003, making it 23+ years old. It is registered with the Registrar of Companies, Mumbai.
Chandra Bhagat Pharma has 63 deals on record (62 market trades, 1 ipo); the latest was in June 2026.
The peers of Chandra Bhagat Pharma by revenue are Chiron Behring Vaccines Private Limited, Cosmas Research Lab Limited, Centurion Healthcare Private Limited, Lovincare Cosmetics Private Limited, Twentyfirst Century Pharmaceuticals Private Limited and 3 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).